Skip to main content
DRMA
NASDAQ Life Sciences

Dermata Therapeutics 将年度净亏损缩减至 756 万美元，确认战略转型

feedReported by Wiseek News
Sentiment info
Neutral
Importance info
8
Price
$1.379
Mkt Cap
$3.884M
52W Low
$1.11
52W High
$23.7
Market data snapshot near publication time

summarizeSummary

Dermata Therapeutics 在其 10-K 文件中报告了年度财务结果，详细说明了截至 2025 年 12 月 31 日的年度净亏损为 756 万美元。这代表着与前一年相比有了 473 万美元的显著改善，营业费用也下降到了 777 万美元。该文件为公司最近宣布的战略转型提供了完整的财务背景，从处方皮肤科转向直接面向消费者（DTC）和企业对企业（B2B）非处方（OTC）/化妆品护肤模式，包括计划于 2026 年中期推出其 Tome Foundational 产品。此外，公司在重新优先分配资源以进行消费品开发之前，已完成了其第 3 阶段 STAR-1 试验，并取得了统计学意义的结果。这种对财务表现和战略执行的全面更新对于投资者来说至关重要，尤其是考虑到公司的微型市值地位。交易者将关注 DTC 转型的成功执行和即将推出的产品发布的财务影响。

在该公告发布时，DRMA的交易价格为$1.38，交易所为NASDAQ，所属行业为Life Sciences，市值约为$388.4万。 52周交易区间为$1.11至$23.70。 这则新闻被评估为中性市场情绪，重要性评分为8/10。 来源：Wiseek News。

show_chartPrice Chart

Share this article

Copied!

feed DRMA - Latest Insights

DRMA
Apr 17, 2026, 5:03 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Shareholders to Vote on Significant Dilution and Warrant Repricing Amidst Going Concern
Sentiment: Negative
View Wiseek Article
DRMA
Apr 17, 2026, 5:01 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Shareholders to Vote on Highly Dilutive Warrant Issuance, Repricing, and Equity Plan Expansion
Sentiment: Negative
View Wiseek Article
DRMA
Apr 02, 2026, 8:30 AM EDT
Source: Access Newswire
Importance Score:
7
Dermata Secures Australian Patent Acceptance for Topical Dermal Filler Delivery System
Sentiment: Positive
View Wiseek Article
DRMA
Mar 26, 2026, 5:25 PM EDT
Source: Wiseek News
Importance Score:
8
Dermata Therapeutics Narrows Annual Net Loss to $7.56M, Confirms Strategic Pivot
Sentiment: Neutral
View Wiseek Article
DRMA
Mar 26, 2026, 5:17 PM EDT
Filing Type: 10-K
Importance Score:
9
Dermata Therapeutics Faces Going Concern Amidst Massive Dilutive Financings and Strategic Pivot
Sentiment: Negative
View Wiseek Article
DRMA
Mar 26, 2026, 5:15 PM EDT
Source: Access Newswire
Importance Score:
9
Dermata Raises $15.4M, Launches 'Tome' Skincare Brand in Strategic DTC Pivot
Sentiment: Positive
View Wiseek Article
DRMA
Feb 25, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Director Mary Fisher Resigns from Dermata Therapeutics Board Due to Employer Acquisition
Sentiment: Neutral
View Wiseek Article
DRMA
Feb 03, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Dermata Therapeutics Changes Independent Auditor, Appointing Former Firm CBIZ CPAs
Sentiment: Neutral
View Wiseek Article
DRMA
Jan 29, 2026, 5:12 PM EST
Filing Type: 424B3
Importance Score:
8
Dermata Therapeutics Finalizes Resale Prospectus for 6.2M Shares and Warrants, Securing Potential $8.6M Capital
Sentiment: Neutral
View Wiseek Article
DRMA
Jan 27, 2026, 8:00 AM EST
Filing Type: 424B5
Importance Score:
7
Dermata Therapeutics Updates At-The-Market Offering Capacity to $705,000
Sentiment: Neutral
View Wiseek Article